UY27583A1 - Anticuerpo que inhibe la aactividad del factor de las celulas precursoras y su uso para el tratamiento del asma - Google Patents
Anticuerpo que inhibe la aactividad del factor de las celulas precursoras y su uso para el tratamiento del asmaInfo
- Publication number
- UY27583A1 UY27583A1 UY27583A UY27583A UY27583A1 UY 27583 A1 UY27583 A1 UY 27583A1 UY 27583 A UY27583 A UY 27583A UY 27583 A UY27583 A UY 27583A UY 27583 A1 UY27583 A1 UY 27583A1
- Authority
- UY
- Uruguay
- Prior art keywords
- cell factor
- asthma
- precursor cell
- activity
- treatment
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención provee de anticuerpos humanos específicos para el factor de la células precursoras que contienen por lo menos una CDR derivadas de una biblioteca combinatoria de anticuerpos. La invención provee, además de composiciones farmacéuticas que comprenden los anticuerpos y métodos para tratar al asma. La invención provee, en forma adicional, de métodos para detectar al factor de las células huésped usando los anticuerpos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34217401P | 2001-12-17 | 2001-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY27583A1 true UY27583A1 (es) | 2003-06-30 |
Family
ID=23340685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27583A UY27583A1 (es) | 2001-12-17 | 2002-12-13 | Anticuerpo que inhibe la aactividad del factor de las celulas precursoras y su uso para el tratamiento del asma |
Country Status (8)
Country | Link |
---|---|
US (2) | US7285640B2 (es) |
AR (1) | AR037756A1 (es) |
AU (1) | AU2002361720A1 (es) |
GT (1) | GT200200279A (es) |
HN (1) | HN2002000366A (es) |
TW (1) | TW200305435A (es) |
UY (1) | UY27583A1 (es) |
WO (1) | WO2003051311A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
AR037756A1 (es) * | 2001-12-17 | 2004-12-01 | Bayer Corp | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. |
WO2006002064A2 (en) * | 2004-06-14 | 2006-01-05 | Aerovance, Inc. | Antibody inhibiting stem cell factor activity and use for treatment of asthma |
TW200902555A (en) * | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
US8679490B2 (en) * | 2005-11-07 | 2014-03-25 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
CA2689941C (en) * | 2007-06-25 | 2019-10-29 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
WO2009135001A2 (en) * | 2008-04-30 | 2009-11-05 | University Of Pittsburgh- Commonwealth System Of Higher Education | Methods and compositions for regulating th2 and th17 responses |
CA2737351A1 (en) * | 2008-09-26 | 2010-04-01 | Wyeth Llc | Single chain antibody library design |
ES2808529T3 (es) * | 2011-01-10 | 2021-03-01 | Univ Michigan Regents | Inhibidor del factor de células madre |
KR101384360B1 (ko) * | 2012-05-04 | 2014-04-14 | 아주대학교산학협력단 | Scf 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
WO2015006554A1 (en) | 2013-07-10 | 2015-01-15 | The Regents Of The University Of Michigan | Therapeutic antibodies and uses thereof |
EP3472178A4 (en) | 2016-06-17 | 2020-02-19 | Magenta Therapeutics, Inc. | COMPOSITION AND METHOD FOR DEPLYING CD117 + CELLS |
WO2019066093A1 (ko) * | 2017-09-26 | 2019-04-04 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
JP2022547733A (ja) | 2019-09-16 | 2022-11-15 | オプシディオ, エルエルシー | 腎疾患における抗幹細胞因子抗体及びその使用方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US6187559B1 (en) * | 1997-08-28 | 2001-02-13 | Novartis Ag | Phospholipase D gene |
US6576812B1 (en) * | 1999-05-06 | 2003-06-10 | The Trustees Of Columbia University In The City Of New York | Compound screening assays using a transgenic mouse model of human skin diseases |
AU2001258659A1 (en) * | 2000-05-30 | 2001-12-11 | Ich Productions Limited | Improved methods of transfection |
AR037756A1 (es) * | 2001-12-17 | 2004-12-01 | Bayer Corp | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. |
-
2002
- 2002-12-09 AR ARP020104759A patent/AR037756A1/es unknown
- 2002-12-13 UY UY27583A patent/UY27583A1/es not_active Application Discontinuation
- 2002-12-16 TW TW091136219A patent/TW200305435A/zh unknown
- 2002-12-16 HN HN2002000366A patent/HN2002000366A/es unknown
- 2002-12-16 US US10/320,231 patent/US7285640B2/en not_active Expired - Fee Related
- 2002-12-16 WO PCT/US2002/040227 patent/WO2003051311A2/en not_active Application Discontinuation
- 2002-12-16 AU AU2002361720A patent/AU2002361720A1/en not_active Abandoned
- 2002-12-17 GT GT200200279A patent/GT200200279A/es unknown
-
2004
- 2004-06-14 US US10/867,506 patent/US20050112698A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20030194405A1 (en) | 2003-10-16 |
WO2003051311A2 (en) | 2003-06-26 |
TW200305435A (en) | 2003-11-01 |
AU2002361720A1 (en) | 2003-06-30 |
AR037756A1 (es) | 2004-12-01 |
AU2002361720A8 (en) | 2003-06-30 |
GT200200279A (es) | 2003-07-18 |
HN2002000366A (es) | 2003-04-21 |
US20050112698A1 (en) | 2005-05-26 |
WO2003051311A3 (en) | 2004-09-30 |
US7285640B2 (en) | 2007-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY27583A1 (es) | Anticuerpo que inhibe la aactividad del factor de las celulas precursoras y su uso para el tratamiento del asma | |
NO20170633A1 (no) | Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff . | |
Virard et al. | Cold atmospheric plasma induces a predominantly necrotic cell death via the microenvironment | |
EA200501586A1 (ru) | Фармацевтические продукты | |
ECSP034438A (es) | Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c | |
NO20050795L (no) | Forbindelser, blandinger og fremgangsmater for utnyttelse av samme | |
BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
BRPI0312649A2 (pt) | compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos. | |
AR057807A1 (es) | Formulaciones de anticuerpo anti-cd3 | |
SE0301700D0 (sv) | Novel compounds | |
EE200300475A (et) | Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis | |
ATE430555T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von asthma | |
ES2377720T3 (es) | Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos. | |
EA200801301A1 (ru) | ИНГИБИТОРЫ АКТИВНОСТИ Akt | |
ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
NO20083895L (no) | Anti-IGF-1R human monoklonalantibody formulering | |
AR029851A1 (es) | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c | |
NO20054006D0 (no) | Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer | |
CL2011001215A1 (es) | Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes. | |
BRPI0407234A (pt) | Heterociclos substituìdos | |
CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
BRPI0513944A (pt) | forma substancialmente pura de um composto de quinazolina, uso de um composto de quinazolina e composição | |
NO20072290L (no) | Organiske forbindelser. | |
BRPI0717369A2 (pt) | Composto, medicamento, composição farmacêutica que o contém e uso do composto. | |
CL2007002380A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20101115 |